Boots Dry Cough Syrup 6 Years +
Boots Dry Cough Syrup 6 Years +
Active ingredient mg/5ml
Pholcodine Ph Eur 2.0
Cough suppressant for the relief of acute non-productive (dry, tickly) cough associated with upper respiratory tract infection.
Children 6-12 years: Two 5ml spoonfuls three times a day.
Not more than 3 doses should be given in any 24 hours.
This medicine is contraindicated in children under 6 years of age (See section 4.3).
Children of 6-12 years of age: not to be used for more than 5 days without the advice of a doctor. Parents or carers should seek medical attention if the child's condition deteriorates during treatment.
For oral administration
Do not exceed the stated dose.
Keep all medicines out of the sight and reach of children.
Hypersensitivity to the active substance or any of the excipients
Pholcodine should not be given to subjects in, or at risk of developing respiratory failure, (may depress respiration).
Patients with chronic bronchitis, COPD, bronchiolitis or bronchiectasis due to sputum retention
Patients with renal or hepatic failure
Patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment (see also section 4.5).
Not to be used in children under the age of 6 years.
Should be used with caution in patients with liver or renal disease
Ask a doctor before use if you suffer from a chronic or persistent cough, if you have asthma or are suffering from an acute asthma attack or where cough is accompanied by excessive secretions.
Do not give with any other cough and cold medicine.
Use of pholcodine with alcohol or other CNS depressants may increase the effects on the CNS and cause toxicity in relatively smaller doses.
If symptoms persist consult your doctor.
Not to be used in patients taking MAOIs or within 14 days of stopping treatment.
Interaction with neuromuscular blocking agents (anaphylaxis) has been reported.
The reduction in blood pressure caused by antihypertensives may accentuate the hypotensive effects of pholcodine. Diuretics may have the same effect. Pholcodine may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives and tranquillisers (phenothiazines and tricyclic antidepressants).
The safety of pholcodine during pregnancy and lactation has not been established. Based on the available data for morphine, it would seem likely that use of pholcodine during pregnancy would not be associated with congenital defects and that use of pholcodine during lactation would not be contraindicated. However, its use should be carefully assessed by consideration of small benefits versus potential risk to the foetus or neonate.
This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called a ‘statutory defence’) if:
-The medicine has been prescribed to treat a medical or dental problem and -You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and -It was not affecting your ability to drive safely
The following side effects may be associated with the use of pholcodine: Occasional drowsiness, dizziness, excitation, confusion, sputum retention, vomiting, gastrointestinal disturbances (nausea and constipation) and skin reactions including rash.
Immune system disorders have been noted including hypersensitivity reactions and anaphylaxis.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
It is thought to be of low toxicity, but the effects in overdosage will be potentiated by simultaneous ingestion of alcohol and psychotropic drugs.
Symptoms: These include nausea, drowsiness, restlessness, excitement, ataxia and respiratory depression.
Management: Treatment of overdose should be symptomatic and supportive. Gastric lavage may be of use. In cases of severe poisoning the specific narcotic antagonist nalaxone may be used.
Information for children:
Nalaxone has been used successfully to reverse central or peripheral opioid effects in children (0.01mg/kg body weight). Other treatment option is activated charcoal (1g/kg body weight) if more than 4mg/kg has been ingested within 1 hour, provided the airway can be protected.
Pholcodine is a cough suppressant with mild sedative but little analgesic activity.
Maximum plasma concentrations are attained at 4 to 8 hours after an oral dose. The elimination half life ranges from 32 to 43 hours and volume of distribution is 30-49 l/kg.
Pholcodine is protein bound to the extent of 23.5%.
Pholcodine is metabolised in the liver but undergoes little conjugation.
There is little or no metabolism of pholcodine to morphine and this may account for the lack of analgesic activity, morphine-like side-effects and addictive potential.
There are no preclinical data of relevance to the prescriber which are additional to that already included.
Maltitol liquid Sodium citrate
Citric acid monohydrate Sodium benzoate Blackcurrant Flavour QL80001 Vanilla Flavour Mixture QL78307 Purified water Hydroxyethylcellulose Glycerin Acesulfame K
Do not store above 30°C.
An amber PET bottle with a child resistant polypropylene cap fitted with an expanded polyethylene liner.
Pack size: 100ml, 150ml.
The Boots Company PLC 1 Thane Road West Nottingham NG2 3AA
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
16 July 1996
DATE OF REVISION OF THE TEXT